LeagueNews.co | Robbie Hamilton
Market-leading Kiwi pain relief brand Maxigesic has re-signed for another two years with the NZ Warriors as the club's official pain relief partner.
Maxigesic will feature on the front of the playing shorts of the NRL and NRLW sides while it will also continue to be the presenting partner for the club's weekly recovery report.
Maxigesic, developed and marketed by New Zealand-based AFT Pharmaceuticals, continues to be a major focus in Australasia and the rest of the world, with a landmark United States launch for Maxigesic tablets coming in early 2026, following on from the launch of Maxigesic IV within the US market.
AFT Pharmaceuticals has continued to go from strength to strength in recent years. Listed on both the ASX and NZX, it has significantly expanded its international operations with the development of a series of international business hubs around the world.